The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed May 15, 2023. Its latest SEC filing is a EFFECT from Jun 23, 2023.
10-Q for Q3 FY2023, filed May 15, 2023
The sections below describe the company as of the FY2022 annual report.
Develops, manufactures and sells generic medicines to pharmaceutical distributors, wholesalers and pharmacies.
10-K for FY2022, filed Aug 25, 2022Lannett Company, Inc. and subsidiaries (the “Company,” “Lannett,” “we,” or “us”) was incorporated in 1942 under the laws of the…View ↗
Today, we market more than 100 products, mainly tablet, capsule or liquid oral generic medications. Examples of marketed products include…View ↗
We sell our pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label…View ↗
Customers order medicines by purchase order; Lannett generally receives payment when it ships the products. Some contract manufacturing work is billed over time.
10-K for FY2022, filed Aug 25, 2022Under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company recognizes revenue when (or…View ↗
$340.6M
10-K for FY2022, filed Aug 25, 2022
$340.6M ↗
Lannett contracts with group purchasing organizations and sells to wholesalers, distributors, chain drugstores, pharmacies, hospitals and other healthcare buyers. Some buyers purchase through wholesalers, which distribute the products to them.
10-K for FY2022, filed Aug 25, 2022We enter into contracts with Group Purchasing Organizations (“GPOs”) to sell our products to their members who are our direct and indirect…View ↗
We sell our pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label…View ↗
Sales to wholesale customers include “indirect sales,” which represent sales to third-party entities, such as independent pharmacies…View ↗
We enter into definitive agreements with our indirect customers to establish pricing for certain covered products. Under such agreements…View ↗
Strong and dependable customer relationships have created a positive platform for us to increase our sales volumes. Historically and in…View ↗
10-K for FY2022, filed Aug 25, 2022
We sell our pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label…View ↗
No. It lost $231.6M in FY2022.
10-K for FY2022, filed Aug 25, 2022
−$176.3MView ↗
10-K for FY2022, filed Aug 25, 2022
−$231.6MView ↗
10-K for FY2022, filed Aug 25, 2022
−$15.9MView ↗
10-Q for Q3 FY2023, filed May 15, 2023
−$101.5MView ↗
8-K, filed Jun 20, 2023
The Plan was supported by all major creditor constituencies, including more than 80% of holders of its Senior Secured Notes and 100% of…View ↗
8-K, filed May 3, 2023
The Company entered into the RSA with the significant support of key stakeholders, including holders of more than 80% of its Senior Secured…View ↗
8-K, filed Apr 20, 2023
On April 19, 2023, Lannett Company, Inc. (the “Company”) received a written notice from the New York Stock Exchange (“NYSE”) dated April…View ↗
8-K, filed Apr 14, 2023
On May 16, 2023, John Kozlowski will be leaving Lannett Company, Inc. (the “Company”) to pursue other opportunities. In consideration of…View ↗
Shrank. Revenue fell 50% in 4 years, from $684.6M in FY2018 to $340.6M in FY2022, about 16% a year.
Exited pain-medicine ingredients
The older report described a plan to close its pain-medicine ingredients operation; the latest report says Lannett has exited that business.
10-K for FY2019, filed Aug 28, 2019 10-K for FY2022, filed Aug 25, 2022We are in the process of closing the Cody Labs subsidiary, our controlled substance products API business. We have signed an agreement to…View ↗
Over the past four years, to help manage the recent decline in our sales and profitability, we have made cost and operational discipline…View ↗
Added another insulin development program
The older report described co-development of insulin glargine; the latest report adds insulin aspart to its co-development plans.
10-K for FY2019, filed Aug 28, 2019 10-K for FY2022, filed Aug 25, 2022Similarly, in 2016, the Company announced a strategic partnership with YiChang HEC ChangJiang Pharmaceutical Co., Ltd, an HEC Group…View ↗
In 2016, the Company announced a strategic partnership with YiChang HEC ChangJiang Pharmaceutical Co., Ltd, an HEC Group company, to…View ↗
Competes with Teva Pharmaceutical Industries, Aurobindo Pharma, and Amneal Pharmaceuticals
10-K for FY2022, filed Aug 25, 2022The manufacturing and distribution of generic pharmaceutical products is a highly competitive industry and that competition has intensified…View ↗
Loading...
